|
Title
|
|
|
|
A panel of CSF proteins separates genetic frontotemporal dementia from presymptomatic mutation carriers: a GENFI study.
| |
|
Author
|
|
|
|
| |
|
Institution/Organisation
|
|
|
|
Genetic Frontotemporal Dementia Initiative (GENFI)
| |
|
Abstract
|
|
|
|
| BACKGROUND A detailed understanding of the pathological processes involved in genetic frontotemporal dementia is critical in order to provide the patients with an optimal future treatment. Protein levels in CSF have the potential to reflect different pathophysiological processes in the brain. We aimed to identify and evaluate panels of CSF proteins with potential to separate symptomatic individuals from individuals without clinical symptoms (unaffected), as well as presymptomatic individuals from mutation non-carriers. METHODS A multiplexed antibody-based suspension bead array was used to analyse levels of 111 proteins in CSF samples from 221 individuals from families with genetic frontotemporal dementia. The data was explored using LASSO and Random forest. RESULTS When comparing affected individuals with unaffected individuals, 14 proteins were identified as potentially important for the separation. Among these, four were identified as most important, namely neurofilament medium polypeptide (NEFM), neuronal pentraxin 2 (NPTX2), neurosecretory protein VGF (VGF) and aquaporin 4 (AQP4). The combined profile of these four proteins successfully separated the two groups, with higher levels of NEFM and AQP4 and lower levels of NPTX2 in affected compared to unaffected individuals. VGF contributed to the models, but the levels were not significantly lower in affected individuals. Next, when comparing presymptomatic GRN and C9orf72 mutation carriers in proximity to symptom onset with mutation non-carriers, six proteins were identified with a potential to contribute to a separation, including progranulin (GRN). CONCLUSION In conclusion, we have identified several proteins with the combined potential to separate affected individuals from unaffected individuals, as well as proteins with potential to contribute to the separation between presymptomatic individuals and mutation non-carriers. Further studies are needed to continue the investigation of these proteins and their potential association to the pathophysiological mechanisms in genetic FTD. |
| |
|
Language
|
|
|
|
English
| |
|
Source (journal)
|
|
|
|
JAMA neurology / American Medical Association. - Chicago, Ill., 2013, currens
Molecular neurodegeneration. - London
| |
|
Publication
|
|
|
|
Chicago, Ill.
:
2021
| |
|
ISSN
|
|
|
|
2168-6149
[print]
2168-6157
[online]
| |
|
DOI
|
|
|
|
10.1186/S13024-021-00499-4
| |
|
Volume/pages
|
|
|
|
16
:1
(2021)
| |
|
ISI
|
|
|
|
000723000900001
| |
|
Pubmed ID
|
|
|
|
34838088
| |
|
Full text (Publisher's DOI)
|
|
|
|
| |
|
Full text (open access)
|
|
|
|
| |
|